Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F4GF
|
|||
| Former ID |
DNCL003126
|
|||
| Drug Name |
MK-8998
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H23F3N2O2
|
|||
| Canonical SMILES |
CC(C)C1=CC=C(C=C1)CC(=O)NC(C)C2=NC=C(C=C2)OCC(F)(F)F
|
|||
| InChI |
1S/C20H23F3N2O2/c1-13(2)16-6-4-15(5-7-16)10-19(26)25-14(3)18-9-8-17(11-24-18)27-12-20(21,22)23/h4-9,11,13-14H,10,12H2,1-3H3,(H,25,26)/t14-/m1/s1
|
|||
| InChIKey |
IQIKXZMPPBEWAD-CQSZACIVSA-N
|
|||
| CAS Number |
CAS 953778-58-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00827918) A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.